Amedisys Inc (NASDAQ:AMED) – Jefferies Financial Group increased their FY2020 earnings per share (EPS) estimates for shares of Amedisys in a report issued on Wednesday, July 31st. Jefferies Financial Group analyst B. Tanquilut now expects that the health services provider will post earnings of $4.95 per share for the year, up from their previous estimate of $4.85. Jefferies Financial Group has a “Buy” rating and a $150.00 price target on the stock.
AMED has been the subject of a number of other research reports. Oppenheimer boosted their target price on shares of Amedisys from $140.00 to $150.00 in a research note on Thursday, August 1st. Barclays boosted their target price on shares of Amedisys from $120.00 to $125.00 and gave the stock an “equal weight” rating in a research note on Monday. Royal Bank of Canada boosted their target price on shares of Amedisys to $150.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. ValuEngine upgraded shares of Amedisys from a “hold” rating to a “buy” rating in a research note on Saturday, June 22nd. Finally, BidaskClub upgraded shares of Amedisys from a “buy” rating to a “strong-buy” rating in a research note on Friday, July 26th. Seven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $135.90.
Amedisys (NASDAQ:AMED) last issued its earnings results on Wednesday, July 31st. The health services provider reported $1.21 EPS for the quarter, topping analysts’ consensus estimates of $0.97 by $0.24. The firm had revenue of $492.98 million during the quarter, compared to the consensus estimate of $489.66 million. Amedisys had a net margin of 6.84% and a return on equity of 27.23%. The company’s revenue was up 19.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.00 earnings per share.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Riverbridge Partners LLC acquired a new stake in shares of Amedisys during the second quarter worth about $80,465,000. Norges Bank acquired a new stake in shares of Amedisys during the fourth quarter worth about $68,342,000. Geode Capital Management LLC boosted its stake in shares of Amedisys by 23.4% during the fourth quarter. Geode Capital Management LLC now owns 429,999 shares of the health services provider’s stock worth $50,357,000 after buying an additional 81,573 shares during the period. FMR LLC boosted its stake in shares of Amedisys by 13.4% during the first quarter. FMR LLC now owns 370,789 shares of the health services provider’s stock worth $45,703,000 after buying an additional 43,844 shares during the period. Finally, Deutsche Bank AG boosted its stake in shares of Amedisys by 12.1% during the fourth quarter. Deutsche Bank AG now owns 319,075 shares of the health services provider’s stock worth $37,365,000 after buying an additional 34,553 shares during the period. Institutional investors own 87.98% of the company’s stock.
In other Amedisys news, insider David L. Kemmerly sold 5,000 shares of the company’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $115.17, for a total value of $575,850.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bruce D. Perkins acquired 2,500 shares of the firm’s stock in a transaction on Wednesday, May 15th. The stock was bought at an average price of $111.84 per share, with a total value of $279,600.00. Following the purchase, the director now directly owns 22,088 shares of the company’s stock, valued at $2,470,321.92. The disclosure for this purchase can be found here. Insiders sold 51,278 shares of company stock valued at $6,082,207 in the last 90 days. 2.90% of the stock is currently owned by insiders.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Featured Story: Cost of Equity For A Business, Investors
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.